Suppr超能文献

枸橼酸乙胺嗪强化盐在印度消除淋巴丝虫病的应用。

Diethylcarbamazine citrate-fortified salt for lymphatic filariasis elimination in India.

机构信息

Vector Control Research Centre, Puducherry, India.

National Centre for Vector-Borne Disease Control, Directorate General of Health Services, Ministry of Health and Family Welfare, Government of India, New Delhi, India.

出版信息

Indian J Med Res. 2022 Mar;155(3&4):347-355. doi: 10.4103/ijmr.ijmr_171_22.

Abstract

Lymphatic filariasis (LF) is a vector-borne neglected tropical disease, causing permanent disability. The disease is debilitating and widespread, leading to tremendous productivity and economic loss. The Government of India (GOI) prioritized the elimination of LF through the annual mass drug administration (MDA) programme in 2004 and continued with a single dose of diethylcarbamazine citrate (DEC), 6 mg/kg of body weight, plus albendazole annually over a period of 5-6 years. The GOI had set the target to achieve LF elimination by 2015 and now by 2030. The progress so far has been suboptimal. Much remains to be done as about 84 per cent of the total 328 endemic districts are still under MDA. The major challenge in implementing MDA is poor compliance. It is necessary to have a feasible alternative strategy addressing the above challenge to achieve the desired goal of LF elimination. At this juncture, a well-researched approach, i.e. the use of DEC-fortified salt, also advocated by the World Health Organization, as a unique form of MDA, is proposed. As per this strategy, a low dose of DEC (0.2% w/w) is added to the cooking salt at the manufacturing facility of iodized salt and consumed by the LF-endemic communities for about two years. Many examples of successful use of this strategy for LF elimination in small- and large-scale trials have been documented in India and several other endemic countries in the world. Implementing DEC-iodine-fortified salt is a safe, less expensive, more efficient and prompt approach for achieving the elimination of LF in India. Adverse effects are none or minor and self-limiting. The DEC-fortified salt strategy can easily piggyback on the existing countrywide deployment of iodized salt under the National Iodine Deficiency Disorders Control Programme (NIDDCP), which has achieved a great success in reducing iodine-deficiency disorders such as hypothyroidism. This existing robust programme can be leveraged to launch DEC-fortified salt for the community. If implemented appropriately, this strategy will ensure the complete cessation of LF transmission within two years from its introduction. If the said strategy is implemented in 2022, it is expected that India will be able to achieve the LF elimination by 2024, much before the global target of 2030.

摘要

淋巴丝虫病(LF)是一种由媒介传播的被忽视的热带病,会导致永久性残疾。该疾病具有致残性且广泛存在,导致巨大的生产力和经济损失。印度政府(GOI)于 2004 年通过年度大规模药物治疗(MDA)计划将消除 LF 作为优先事项,并在 5-6 年内继续每年使用一剂柠檬酸双羟萘酸噻嘧啶(DEC),剂量为 6 毫克/公斤体重,外加阿苯达唑。GOI 设定的目标是到 2015 年实现 LF 消除,现在目标是到 2030 年。到目前为止,进展并不理想。仍有许多工作要做,因为在总共 328 个流行地区中,仍有 84%以上仍在进行 MDA。实施 MDA 的主要挑战是低合规性。有必要制定一种可行的替代策略来应对上述挑战,以实现消除 LF 的预期目标。在这一时刻,建议采用一种经过充分研究的方法,即使用 DEC 强化盐,这也是世界卫生组织所倡导的一种独特形式的 MDA。根据该策略,在碘盐生产厂将低剂量 DEC(0.2%w/w)添加到烹饪盐中,并由 LF 流行社区消费大约两年。在印度和世界上其他几个流行国家的小规模和大规模试验中,已经有许多成功使用该策略消除 LF 的例子。在印度,实施 DEC-碘强化盐是一种安全、成本更低、更有效和更迅速的方法,可以实现 LF 的消除。不良反应很少或没有,且具有自限性。DEC 强化盐策略可以轻松地利用国家碘缺乏症控制规划(NIDDCP)下在全国范围内部署的碘盐,该规划在减少甲状腺功能减退等碘缺乏症方面取得了巨大成功。现有的强大计划可以用于向社区推出 DEC 强化盐。如果适当实施,该策略将确保从推出之日起两年内完全停止 LF 的传播。如果该策略于 2022 年实施,预计印度将能够在 2024 年之前,即全球目标 2030 年之前实现 LF 消除。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/33b4/9707683/8c3c4799ef15/IJMR-155-347-g001.jpg

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验